Retatrutide, developed by Soma Pharmaceuticals , is receiving increasing attention as a potential method for metabolic control . This dual-action drug merges the properties of a GLP-1 receptor activator and a GIP receptor activator , designed to simply promote metabolic improvements but also address underlying metabolic conditions . Initial clinica